"Currently, Japan is at the forefront of Virus Therapy, but it took them a full twenty years to go from research to application, and the results are not ideal. Their product can only be used as an adjunct, such as to shrink the tumor before surgery to facilitate the procedure. Moreover, our approach is completely different from theirs. They only use viruses as markers to attract the immune system to attack the tumor. Essentially, this is still considered immunotherapy."
"Our virus therapy truly exploits the virus for penetration, marking, and hunting, relying on the virus to perform all these functions. Thus, some steps have to be approached in reverse; for instance, the invisibility cloak feature of the α47 gene—we are not eliminating this feature, but enhancing it."
